Across TCGA pan-cancer cohorts, ZNF192P1 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated ZNF192P1 data layer compared with 21 for mass-spec protein.
The strongest signal is observed in thymoma (THYM), where higher ZNF192P1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZNF192P1 expression acts as an unfavorable survival marker.
THYM are the cancer types where ZNF192P1 Mutation most reproducibly stratifies survival.